Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1985 Jan 1;161(1):1–17. doi: 10.1084/jem.161.1.1

Importance of immunoglobulin isotype in human antibody-dependent, cell- mediated cytotoxicity directed by murine monoclonal antibodies

PMCID: PMC2187540  PMID: 3918141

Abstract

Using the fluorescence activated cell sorter to select rare IgG2a- and IgG2b-producing variants, we developed switch variant families of hybridomas from IgG1-producing hybridomas, ME1 and MA2.1. The IgG2a and IgG2b antibodies produced by such switch variants have the same binding activities for HLA as the IgG1 antibodies produced by the parent hybridomas. Using these antibodies, we directly compared the IgG1, IgG2a, and IgG2b murine Ig isotypes for their capacities to direct human peripheral blood lymphocytes (PBL) in antibody-dependent cell- mediated cytotoxicity (ADCC) against a B lymphoblastoid cell line. We demonstrate that, for antibodies of identical binding affinity and specificity, the murine IgG2a isotype is the most effective in directing ADCC by human effector cells. The murine IgG2b directs intermediate levels of ADCC activity while IgG1 is inactive. We identified the effector cells in human PBL that mediate IgG2a or IgG2b ADCC as nonadherent killer (K) cells. These cells express the C3bi receptor and have cytolytic activity which is specifically blocked by a monoclonal antibody (anti-Leu-11a) that binds the Fc receptor (FcR) of such cells. Finally, FcR-bearing K cells bind to target cell-bound, rather than free, IgG2a or IgG2b molecules.

Full Text

The Full Text of this article is available as a PDF (966.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abo T., Balch C. M. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol. 1981 Sep;127(3):1024–1029. [PubMed] [Google Scholar]
  2. Anderson C. L. Isolation of the receptor for IgG from a human monocyte cell line (U937) and from human peripheral blood monocytes. J Exp Med. 1982 Dec 1;156(6):1794–1806. doi: 10.1084/jem.156.6.1794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beller D. I., Springer T. A., Schreiber R. D. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982 Oct 1;156(4):1000–1009. doi: 10.1084/jem.156.4.1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cosimi A. B., Burton R. C., Colvin R. B., Goldstein G., Delmonico F. L., LaQuaglia M. P., Tolkoff-Rubin N., Rubin R. H., Herrin J. T., Russell P. S. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 1981 Dec;32(6):535–539. doi: 10.1097/00007890-198112000-00018. [DOI] [PubMed] [Google Scholar]
  5. Dangl J. L., Herzenberg L. A. Selection of hybridomas and hybridoma variants using the fluorescence activated cell sorter. J Immunol Methods. 1982;52(1):1–14. doi: 10.1016/0022-1759(82)90344-1. [DOI] [PubMed] [Google Scholar]
  6. Dillman R. O., Shawler D. L., Sobol R. E., Collins H. A., Beauregard J. C., Wormsley S. B., Royston I. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood. 1982 May;59(5):1036–1045. [PubMed] [Google Scholar]
  7. Ellis S. A., Taylor C., McMichael A. Recognition of HLA-B27 and related antigen by a monoclonal antibody. Hum Immunol. 1982 Aug;5(1):49–59. doi: 10.1016/0198-8859(82)90030-1. [DOI] [PubMed] [Google Scholar]
  8. Ey P. L., Prowse S. J., Jenkin C. R. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978 Jul;15(7):429–436. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
  9. Ey P. L., Russell-Jones G. J., Jenkin C. R. Isotypes of mouse IgG--I. Evidence for 'non-complement-fixing' IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol Immunol. 1980 Jun;17(6):699–710. doi: 10.1016/0161-5890(80)90139-x. [DOI] [PubMed] [Google Scholar]
  10. Goding J. W. Conjugation of antibodies with fluorochromes: modifications to the standard methods. J Immunol Methods. 1976;13(3-4):215–226. doi: 10.1016/0022-1759(76)90068-5. [DOI] [PubMed] [Google Scholar]
  11. Greenberg A. H., Lydyard P. M. Observations of IgG1 anti-DNP hybridoma-mediated ADCC and the failure of three IgM anti-DNP hybridomas to mediate ADCC. J Immunol. 1979 Aug;123(2):861–869. [PubMed] [Google Scholar]
  12. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  13. Hellström I., Hellström K. E., Yeh M. Y. Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas. Int J Cancer. 1981 Mar 15;27(3):281–285. doi: 10.1002/ijc.2910270305. [DOI] [PubMed] [Google Scholar]
  14. Herlyn D., Herlyn M., Steplewski Z., Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979 Aug;9(8):657–659. doi: 10.1002/eji.1830090817. [DOI] [PubMed] [Google Scholar]
  15. Herlyn D., Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4761–4765. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hirayama N., Hirano T., Köhler G., Kurata A., Okumura K., Ovary Z. Biological activities of antitrinitrophenyl and antidinitrophenyl mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1982 Jan;79(2):613–615. doi: 10.1073/pnas.79.2.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Huang C. M., Parsons M., Oi V. T., Huang H. J., Herzenberg L. A. Genetic characterization of mouse immunoglobulin allotypic determinants (allotopes) defined by monoclonal antibodies. Immunogenetics. 1983;18(4):311–321. doi: 10.1007/BF00372464. [DOI] [PubMed] [Google Scholar]
  18. Imai K., Ng A. K., Ferrone S. Characterization of monoclonal antibodies to human melanoma-associated antigens. J Natl Cancer Inst. 1981 Mar;66(3):489–496. [PubMed] [Google Scholar]
  19. Imai K., Pellegrino M. A., Wilson B. S., Ferrone S. Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell Immunol. 1982 Sep 15;72(2):239–247. doi: 10.1016/0008-8749(82)90472-5. [DOI] [PubMed] [Google Scholar]
  20. Lanier L. L., Le A. M., Phillips J. H., Warner N. L., Babcock G. F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983 Oct;131(4):1789–1796. [PubMed] [Google Scholar]
  21. McCarley D. L., Shah V. O., Weiner R. S. Purified human monocyte subsets as effector cells in antibody-dependent cellular cytotoxicity (ADCC). J Immunol. 1983 Oct;131(4):1780–1783. [PubMed] [Google Scholar]
  22. McMichael A. J., Parham P., Rust N., Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol. 1980 Sep;1(2):121–129. doi: 10.1016/0198-8859(80)90099-3. [DOI] [PubMed] [Google Scholar]
  23. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 1981 Aug 1;2(8240):226–230. doi: 10.1016/s0140-6736(81)90475-x. [DOI] [PubMed] [Google Scholar]
  24. Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982 Mar 4;306(9):517–522. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
  25. Oldham R. K. Monoclonal antibodies in cancer therapy. J Clin Oncol. 1983 Sep;1(9):582–590. doi: 10.1200/JCO.1983.1.9.582. [DOI] [PubMed] [Google Scholar]
  26. Parham P., Kipps T. J., Ward F. E., Herzenberg L. A. Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. Hum Immunol. 1983 Oct;8(2):141–151. doi: 10.1016/0198-8859(83)90009-5. [DOI] [PubMed] [Google Scholar]
  27. Perlmann H., Perlmann P., Moretta L., Rönnholm M. Regulation of IgG antibody-dependent cellular cytotoxicity in vitro by IgM antibodies. Scand J Immunol. 1981 Jul;14(1):47–60. doi: 10.1111/j.1365-3083.1981.tb00183.x. [DOI] [PubMed] [Google Scholar]
  28. Perlmann P., Perlmann H., Wigzell H. Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells. Transplant Rev. 1972;13:91–114. doi: 10.1111/j.1600-065x.1972.tb00061.x. [DOI] [PubMed] [Google Scholar]
  29. Perussia B., Acuto O., Terhorst C., Faust J., Lazarus R., Fanning V., Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J Immunol. 1983 May;130(5):2142–2148. [PubMed] [Google Scholar]
  30. Perussia B., Fanning V., Trinchieri G. A human NK and K cell subset shares with cytotoxic T cells expression of the antigen recognized by antibody OKT8. J Immunol. 1983 Jul;131(1):223–231. [PubMed] [Google Scholar]
  31. Perussia B., Trinchieri G., Cerottini J. C. Functional studies of Fc receptor-bearing human lymphocytes: effect of treatment with proteolytic enzymes. J Immunol. 1979 Aug;123(2):681–687. [PubMed] [Google Scholar]
  32. Perussia B., Trinchieri G., Jackson A., Warner N. L., Faust J., Rumpold H., Kraft D., Lanier L. L. The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol. 1984 Jul;133(1):180–189. [PubMed] [Google Scholar]
  33. Phillips J. H., Babcock G. F. NKP-15: a monoclonal antibody reactive against purified human natural killer cells and granulocytes. Immunol Lett. 1983 Mar;6(3):143–149. doi: 10.1016/0165-2478(83)90096-2. [DOI] [PubMed] [Google Scholar]
  34. Ralph P., Nakoinz I. Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes. J Immunol. 1983 Aug;131(2):1028–1031. [PubMed] [Google Scholar]
  35. Ralph P., Nakoinz I., Diamond B., Yelton D. All classes of murine IgG antibody mediate macrophage phagocytosis and lysis of erythrocytes. J Immunol. 1980 Nov;125(5):1885–1888. [PubMed] [Google Scholar]
  36. Shen L., Fanger M. W. Secretory IgA antibodies synergize with IgG in promoting ADCC by human polymorphonuclear cells, monocytes, and lymphocytes. Cell Immunol. 1981 Mar 15;59(1):75–81. doi: 10.1016/0008-8749(81)90435-4. [DOI] [PubMed] [Google Scholar]
  37. Steplewski Z., Herlyn D., Maul G., Koprowski H. Hypothesis: macrophages as effector cells for human tumor destruction mediated by monoclonal antibody. Hybridoma. 1983;2(1):1–5. doi: 10.1089/hyb.1983.2.1. [DOI] [PubMed] [Google Scholar]
  38. Steplewski Z., Lubeck M. D., Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 1983 Aug 26;221(4613):865–867. doi: 10.1126/science.6879183. [DOI] [PubMed] [Google Scholar]
  39. Terhorst C., Robb R., Jones C., Strominger J. L. Further structural studies of the heavy chain of HLA antigens and its similarity to immunoglobulins. Proc Natl Acad Sci U S A. 1977 Sep;74(9):4002–4006. doi: 10.1073/pnas.74.9.4002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Todd R. F., 3rd, Nadler L. M., Schlossman S. F. Antigens on human monocytes identified by monoclonal antibodies. J Immunol. 1981 Apr;126(4):1435–1442. [PubMed] [Google Scholar]
  41. Ways J. P., Parham P. The binding of monoclonal antibodies to cell-surface molecules. A quantitative analysis with immunoglobulin G against two alloantigenic determinants of the human transplantation antigen HLA-A2. Biochem J. 1983 Nov 15;216(2):423–432. doi: 10.1042/bj2160423. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES